Scientific article

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Published inThe Lancet Neurology, vol. 18, no. 11, p. 1034-1044
Publication date2019

Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia.

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease/cerebrospinal fluid/epidemiology/pathology
  • Amyloid beta-Peptides/cerebrospinal fluid
  • Biomarkers/cerebrospinal fluid
  • Cognitive Dysfunction/cerebrospinal fluid/pathology
  • Disease Progression
  • Europe/epidemiology
  • Female
  • Follow-Up Studies
  • Hippocampus/pathology
  • Humans
  • Kaplan-Meier Estimate
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multicenter Studies as Topic/statistics & numerical data
  • Nerve Degeneration
  • Neuroimaging
  • North America/epidemiology
  • Organ Size
  • Peptide Fragments/cerebrospinal fluid
  • Phosphorylation
  • Prognosis
  • Proportional Hazards Models
  • Protein Processing, Post-Translational
  • tau Proteins/cerebrospinal fluid/chemistry
Citation (ISO format)
VAN MAURIK, Ingrid S et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. In: The Lancet Neurology, 2019, vol. 18, n° 11, p. 1034–1044. doi: 10.1016/S1474-4422(19)30283-2
Main files (1)
Article (Published version)
Secondary files (1)
ISSN of the journal1474-4422

Technical informations

Creation07/10/2020 12:20:00 PM
First validation07/10/2020 12:20:00 PM
Update time03/15/2023 10:19:07 PM
Status update03/15/2023 10:19:03 PM
Last indexation01/17/2024 10:25:43 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack